-

STATE OF CONNECTICUT
DEPARTMENT OF PUBLIC HEALTH

Manisha Juthani, MD
Commissioner

Ned Lamont
Governor

Susan Bysiewicz
Lt. Governor

To: **Health Partner/Providers/Local Health Departments**
From: **Josh Hoffner, DO, MPH, Public Health Physician**
Lynn Sosa, MD, State Epidemiologist
Subject: **Adverse Events Following Ceftriaxone Administration**
Date: **February 20, 2025**

The Centers for Disease Control and Prevention (CDC), in collaboration with state and local health departments, is investigating reports of serious adverse events, including deaths, following receipt of injectable ceftriaxone; this includes administration via intramuscular and intravenous routes. To date, events have not been associated with a single product manufacturer or lot and a definitive causal link to ceftriaxone has not been established. There is no recommendation to withhold ceftriaxone or not use ceftriaxone where it is recommended at this time.

CDC is requesting reports of serious adverse events following the administration of ceftriaxone to assist with the ongoing investigation. Adverse events, occurring since September 1, 2024, that meet the following criteria, should be reported:

1. Occurred within 6 hours after receipt of injectable* ceftriaxone in a non-ICU setting, and
2. Resulted in death or required cardiopulmonary resuscitation**, and
3. Not attributed by the treating provider(s) to a cause other than ceftriaxone administration***

**including both intramuscular and intravenous routes of administration*

***cardiopulmonary resuscitation defined as the use of chest compressions and mechanical ventilation or provision of rescue breaths to maintain circulatory flow and oxygenation during cardiac arrest*

****such as known infection, other underlying medical condition, or exposure to a medication or medical product other than ceftriaxone*

Adverse events meeting the above criteria can be reported to CT DPH at DPH.HAIAR@ct.gov or by contacting the CT DPH Epidemiology Program at (860) 509-7994. Healthcare providers should also report serious adverse events that might be associated with a medical product to FDA's MedWatch Program at 1-800-332-1088 or via their website www.fda.gov/medwatch and to the product manufacturer.